Product Description
Mechanisms of Action: 5-HT2 Antagonist,H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Chile | China | Cyprus | Czech | Denmark | Egypt | Finland | France | Germany | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Russia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: MIKEL URRETAVIZCAYARACHAGA
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Parasomnias|Dyssomnias|Depressive Disorder|Stress Disorders, Post-Traumatic
Phase 3: Depressive Disorder, Major|Dementia|Tic Disorders|Depressive Disorder|Psychophysiologic Disorders|Schizophrenia
Phase 2: Stress Disorders, Post-Traumatic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| INTENSIFY MDD | P3 |
Unknown Status |
Depressive Disorder, Major |
2026-06-30 |
|
| 2021-TX-002 | P4 |
Recruiting |
Depressive Disorder|Dyssomnias|Parasomnias |
2025-12-01 |
|
| PTF 5 | P2 |
Completed |
Stress Disorders, Post-Traumatic |
2020-03-18 |
|
| PTF5 | P4 |
Completed |
Dyssomnias|Stress Disorders, Post-Traumatic|Parasomnias|Depressive Disorder |
2019-06-01 |